NasdaqGM:IIN

Stock Analysis Report

Executive Summary

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.

Risks

  • IntriCon has significant price volatility in the past 3 months.

Share Price & News

How has IntriCon's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

NasdaqGM:IIN

1.9%

US Medical Equipment

2.1%

US Market


1 Year Return

-73.5%

NasdaqGM:IIN

13.6%

US Medical Equipment

-0.04%

US Market

IIN underperformed the Medical Equipment industry which returned 14% over the past year.

IIN underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

IINIndustryMarket
7 Day-2.8%1.9%2.1%
30 Day3.7%-0.2%-3.2%
90 Day-29.6%10.2%2.8%
1 Year-73.5%-73.5%14.5%13.6%2.2%-0.04%
3 Year281.7%281.7%70.2%65.0%41.5%32.3%
5 Year165.1%165.1%133.6%106.8%55.0%37.8%

Price Volatility Vs. Market

How volatile is IntriCon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IntriCon undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

IntriCon's share price is below the future cash flow value, and at a moderate discount (> 20%).

IntriCon's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

IntriCon is loss making, we can't compare its value to the US Medical Equipment industry average.

IntriCon is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for IntriCon, we can't assess if its growth is good value.


Price Based on Value of Assets

IntriCon is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is IntriCon expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

81.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

IntriCon's revenue is expected to grow by 13.5% yearly, however this is not considered high growth (20% yearly).

IntriCon's earnings are expected to grow significantly at over 20% yearly.

IntriCon's revenue growth is expected to exceed the United States of America market average.

IntriCon's earnings growth is expected to exceed the United States of America market average.

IntriCon's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if IntriCon will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has IntriCon performed over the past 5 years?

12.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

IntriCon does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare IntriCon's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare IntriCon's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if IntriCon has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if IntriCon has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if IntriCon improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is IntriCon's financial position?


Financial Position Analysis

IntriCon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

IntriCon's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

IntriCon's level of debt (0%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (48.2% vs 0% today).

Operating cash flow is negative therefore debt is not well covered.

IntriCon has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are -7.4834063208201E+16x debt.


Next Steps

Dividend

What is IntriCon's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate IntriCon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate IntriCon's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as IntriCon has not reported any payouts.

Unable to verify if IntriCon's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as IntriCon has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of IntriCon's salary, the management and board of directors tenure and is there insider trading?

18.3yrs

Average management tenure


CEO

Mark Gorder (72yo)

18.3yrs

Tenure

US$937,868

Compensation

Mr. Mark S. Gorder has been the Chief Executive Officer and President of Intricon Corp., an affiliate of IntriCon Tibbetts Corporation since April 2001. He has been a Director of Intricon Corp., since Janu ...


CEO Compensation Analysis

Mark's remuneration is about average for companies of similar size in United States of America.

Mark's compensation has increased whilst company is loss making.


Management Age and Tenure

18.3yrs

Average Tenure

60yo

Average Age

The average tenure for the IntriCon management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

10.1yrs

Average Tenure

71.5yo

Average Age

The average tenure for the IntriCon board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Mark Gorder (72yo)

    CEO, President & Director

    • Tenure: 18.3yrs
    • Compensation: US$937.87k
  • Michael Geraci (60yo)

    Senior Vice President of Sales & Marketing

    • Tenure: 24.6yrs
    • Compensation: US$519.07k
  • Dennis Gonsior (60yo)

    Senior Vice President of Global Operations

    • Tenure: 23.6yrs
    • Compensation: US$495.14k
  • J. Longval (42yo)

    Executive VP

    • Tenure: 13.1yrs
    • Compensation: US$520.00k
  • Greg Gruenhagen (65yo)

    Senior Vice President of Quality & Regulatory Affairs

    • Tenure: 0.3yrs
    • Compensation: US$471.20k
  • Cari Sather

    Director of Human Resources

    • Tenure: 0.0yrs

Board Members

  • Mark Gorder (72yo)

    CEO, President & Director

    • Tenure: 18.3yrs
    • Compensation: US$937.87k
  • Nicholas Giordano (76yo)

    Director

    • Tenure: 18.7yrs
    • Compensation: US$122.50k
  • Ray Huggenberger (60yo)

    Director

    • Tenure: 0.3yrs
  • Robert Masucci (81yo)

    Director

    • Tenure: 17.5yrs
    • Compensation: US$120.00k
  • Philip Smith (51yo)

    Chairman of the Board

    • Tenure: 0.3yrs
    • Compensation: US$109.25k
  • Philip Seamon (71yo)

    Director Emeritus

    • Tenure: 2.7yrs
    • Compensation: US$104.00k

Company Information

IntriCon Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IntriCon Corporation
  • Ticker: IIN
  • Exchange: NasdaqGM
  • Founded: 1930
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$153.796m
  • Shares outstanding: 8.76m
  • Website: https://www.intricon.com

Number of Employees


Location

  • IntriCon Corporation
  • 1260 Red Fox Road
  • Arden Hills
  • Minnesota
  • 55112
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IINNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1968
SLJDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1968

Biography

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company oper ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:55
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.